BOSTON ( TheStreet) -- Welcome to Biotech Stock Live Chat: Hurricane Sandy edition.
First, let me say I hope everyone is safe and as comfortable as possible following a crazy day and night. Here just north and west of Boston, we managed to get through relatively unscathed but I know a lot of people without power or with significant damage to their homes. My sympathies.
U.S. stock markets are closed for a second straight day due to the storm, so while we're all sitting around (or taking a break from Sandy clean up) let's spend an hour or so talking biotech stocks and biotech investing.The floor is yours. I'm happy to discuss Amarin (AMRN) and the outlook for the pending launch of its prescription fish-oil pill Vascepa. I know many of you are very bullish on Amarin's future so make your case here in the live blog. Obesity drug stocks -- Vivus (VVUS), Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX) -- are always a good topic. Biotech earnings season has been interrupted due to the storm but we will get reports this week from Onyx Pharmaceuticals (ONNXX) and Medivation (MDVN), giving us the first peek at new cancer drug launches. Also scheduled to report: Vertex Pharmaceuticals (VRTX), Dendreon (DNDN), Spectrum Pharmaceuticals (SPPI) and Incyte (INCY). Let's discuss. Sarepta Therapeutics (SRPT): Why is the stock down so much since early October? What are the chances for eteplirsen accelerated approval? Let's chat about these stocks or any other biotech investing question you might have. Thanks for participating. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV